PI-10 The evaluation of serological profiles and the seroprevalence of Ebstein Barr virus among various age groups at Izmir Tepecik Educational and Research Hospital, Turkey: preliminary results

Objective: Epstein-Barr virus (EBV) can cause different clinical pictures from infectious mononucleosis (IM) to malignancies such as B-cell lymphomas, Burkitt’s lymphoma, nasopharyngeal carcinoma, and Hodgkin lymphoma. VCA-IgM, VCA-IgG, EBNA-1 IgG antibodies are the most commonly used antibodies in revealing the serological profile. This study aimed to examine the serological profiles of patients with suspected EBV infection and to interpret the atypical profiles encountered. Methods: The results of VCA-IgM, VCA-IgG, and EBNA-1 IgG antibodies studied in the Microbiology Laboratory between 2017-2019 were evaluated retrospectively. EBV serological tests (VCA-IgM, VCA-IgG, and EBNA-1 IgG) were performed according to the manufacturer’s recommendations using the chemiluminescent microparticle immunoassay (CMIA) method (Architect, Abbott, Wiesbaden, Germany). Results: Of the 2486 patients evaluated, 1341 (53.9%) were male, 1145 (46.1%) were female, and the average age was determined as 16.93 ± 19.5. EBV past infection was detected in 56.65% of the cases, the acute infection was detected in 17.25%, and 21.09% did not encounter EBV. Atypical serological profile was detected in 5.01%. As an atypical profile, the most common positivity of three antibodies together (3.90%), then isolated VCA-IgG positivity (0.91%), and isolated EBNA-1 IgG positivity (0.20%) were determined. It was determined that 24.24% of the cases with an atypical profile were immunosuppressive patient. Conclusions: The rate of encountering EBV in our study is 78.91%. The atypical EBV serological profile rate was found to be 5.01%. Approximately one-fourth of the cases with an atypical profile was found to be in the patient group with immune disorders. It is thought that antibody tests are not sufficient to determine the stage of infection, especially in these patient groups, and further tests should be performed. It has been demonstrated that serological monitoring is required for the interpretation of atypical profiles. Keywords: Epstein-Barr virüs, serological tests, chemiluminescent microparticle immunoassay (CMIA), atypical serological profile

Download Full-text

AB0723 Seroprevalence of epstein-barr virus and cytomegalovirus in systemic sclerosis patients: preliminary results

10.1136/annrheumdis-2018-eular.6755 ◽

2018 ◽

Author(s):

A.C. Trombetta ◽

V. Tomatis ◽

E. Alessandri ◽

S. Paolino ◽

C. Pizzorni ◽

...

Keyword(s):

Systemic Sclerosis ◽

Epstein Barr Virus ◽

Preliminary Results ◽

Barr Virus ◽

Epstein Barr

Download Full-text

Rectal plasmablastic lymphoma in Ebstein Barr virus positive and human immunodeficiency virus negative subject after external radiation therapy for prostatic cancer

Acta Gastro Enterologica Belgica ◽

10.51821/84.4.018 ◽

2021 ◽

Vol 84 (4) ◽

pp. 659-661

Author(s):

L Bricman ◽

P Yengue ◽

C Miscu ◽

S Junius ◽

F Waignein ◽

...

Keyword(s):

Human Immunodeficiency Virus ◽

Plasmablastic Lymphoma ◽

Barr Virus ◽

Immunodeficiency Virus ◽

Ebstein Barr Virus ◽

External Radiation Therapy ◽

Negative Subject ◽

Aggressive Subtype ◽

Hiv Negative

Plasmablastic lymphoma (PBL) represents a rare and aggressive subtype of diffuse large B cells lymphoma (DLBCL) most associated with the human immunodeficiency virus (HIV). Prognosis remains poor despite various treatment approaches. We describe an evolution at six months of HIV negative PBL and Ebstein Barr virus (EBV) positive PBL with chemotherapy. Role of radiotherapy is still unclear.

Download Full-text

Pediatrik lenfomalarda histopatolojik subtip ve Ebstein-Barr virus ilişkisi: immünohistokimyasal ve in situ hibridizasyon çalışması

Cukurova Medical Journal ◽

10.17826/cumj.368637 ◽

2018 ◽

Vol 43 (4) ◽

pp. 868-875

Author(s):

Emine Kılıç Bağır ◽

Arbil Açıkalın ◽

Melek Ergin ◽

Gülay Sezgin ◽

Serhan Küpeli ◽

...

Keyword(s):

Barr Virus ◽

Ebstein Barr Virus

Download Full-text

Epstein-Barr Virus Infection

Pediatrics in Review ◽

10.1542/pir.15.2.63 ◽

1994 ◽

Vol 15 (2) ◽

pp. 63-68

Author(s):

William A. Durbin ◽

John L. Sullivan

Keyword(s):

Epstein Barr Virus ◽

Western Europe ◽

Age Groups ◽

The United States ◽

The Philippines ◽

Epstein Barr Virus Infection ◽

Barr Virus ◽

The Usa ◽

Epstein Barr ◽

Barr Virus Infection

Introduction Virtually all humans become infected with Epstein-Barr virus (EBV). The vast majority of these infections are inapparent, occur early in life, and are associated with lifelong latent infection and persistent shedding of virus. Epidemiology The prevalence of antibody to EBV has been determined in many age groups throughout the world. In developing and tropical areas, infection takes place early in life and is inapparent, with most children demonstrating antibody by age 6 years. Infection is believed to be related to hygiene and crowding as well as to cultural patterns that lead to exposure to saliva (eg, prechewing of food). In contrast, infection in Western Europe and the United States in childhood is less common, with only 35% to 50% of 5-year-olds demonstrating antibody. Infectious mononucleosis (IM) emerges as a significant clinical entity only in populations where a sizable percentage of young adults lack immunity to EBV. Thus, IM is unknown among college freshman in Thailand or the Philippines, virtually all of whom have antibody to EBV at the time of admission. On the other hand, in schools in the USA and England, where the susceptibility percentage is in the range of 35% to 50%, infection is seen commonly. In such university settings, approximately 12% of susceptible students become infected with EBV during the freshman year.

Download Full-text